Pharmaxis' Bronchitol inhaler has encouraging Phase 3 trial results for...
Australian listed pharmaceutical company Pharmaxis (ASX:PXS, Nasdaq:PXSL) has received encourgaging results for its recently completed international Phase III trial of the company's Bronchitol portable...
View ArticlePharmaxis Ltd buoyed by asthma study results
Australian pharmaceutical company Pharmaxis (ASX: PXS) today announced the successful completion of a Phase IIa dose profiling study with its new anti‐inflammatory agent ASM8 in patients with allergic...
View ArticlePharmaxis in pre-open pending European Bronchitol marketing application...
Pharmaxis (ASX: PXS) has been granted a trading halt by the ASX pending an update in relation to its European marketing application for Bronchitol expected by Wednesday 25 May 2011. Bronchitol is a...
View ArticlePharmaxis in pre-open pending re-examination of Bronchitol®
Pharmaxis (ASX: PXS) has been granted a trading halt by the ASX, due to the pending details of some announcements which may impact the company.Pharmaxis said in a request to the ASX, 'The European...
View ArticlePharmaxis receives European committee nod to move to marketing approval of...
Pharmaxis (ASX: PXS) is expecting to receive European marketing authorisation for its cystic fibrosis drug in January next year after the Committee for Medicinal Products for Human Use (CHMP)...
View ArticlePharmaxis’ cystic fibrosis drug approved in UK
Pharmaxis (ASX: PXS) has received a positive recommendation from the National Institute for Health and Clinical Excellence in the UK for its cystic fibrosis treatment, Bronchitol®, which clears the way...
View ArticlePharmaxis Bronchitol® drug review by FDA, due Thursday
Pharmaxis (ASX:PXS) will report on a review of Bronchitol® for the treatment of cystic fibrosis by an independent expert advisory panel to the U.S. Food and Drug Administration.The Pulmonary-Allergy...
View ArticlePharmaxis achieves Phase 3 clinical trial milestone for bronchiectasis
Pharmaxis (ASX:PXS) has formally completed the Phase 3 international trial assessing the effectiveness of Bronchitol in people with bronchiectasis. The clinical trial which started in October 2009, was...
View ArticlePharmaxis Limited receives FDA letter for its cystic fibrosis drug
Pharmaxis Limited (ASX: PXS) is in pre-open this morning after the ASX granted a trading halt after the company received the Complete Response Letter from the U.S. Food and Drug Administration...
View ArticlePharmaxis appoints Brazilian distributor for Bronchitol® cystic fibrosis drug
Pharmaxis (ASX:PXS) has appointed United Medical as its exclusive distributor and sales representative for Bronchitol® cystic fibrosis treatment in Brazil.United Medical, a well‐established healthcare...
View ArticlePharmaxis Limited to reveal chronic respiratory trial results
Pharmaxis Limited (ASX: PXS) has received the top line results for its Phase III bronchiectasis clinical trial of Bronchitol® known as “B305”, which is a drug designed to reduce the amount of mucus...
View ArticlePharmaxis Limited and Valeant Pharmaceuticals team up in Eastern European
Pharmaxis Limited (ASX: PXS) will gain exposure to Poland and ten other Eastern European countries for its Bronchitol® cystic fibrosis drug, after appointing a Valeant Pharmaceuticals International...
View ArticlePharmaxis receives $776,646 in Australian Research Council grants for...
Pharmaxis (ASX:PXS) has been awarded a combined $776,646 from the Australian Research Council for two of its projects focusing on fibrotic research being conducted at the University of Sydney.Pharmaxis...
View ArticlePharmaxis’ Bronchitol cystic fibrosis treatment receives nod from Scotland...
Pharmaxis’ (ASX: PXS) Bronchitol non‐antibiotic therapy has been accepted for used by the National Health Service in Scotland for the treatment of adult cystic fibrosis patients.Bronchitol, a...
View ArticlePharmaxis’ shares catch an uplift
Pharmaxis’ (ASX: PXS) shares closed 13.6% firmer yesterday at $0.125, with volume strong at five million shares traded.This was the highest volume day for the company in six-weeks.Pharmaxis' Bronchitol...
View ArticlePharmaxis’ share volume jumps
Trading in Pharmaxis’ (ASX: PXS) shares jumped yesterday with close to four times the recent daily volume being traded in one day.In total 1.5 million shares changed hands, with the stock finishing...
View ArticlePharmaxis Limited granted trading halt
Pharmaceutical development Pharmaxis Limited (ASX:PXS) has been granted a trading halt this morning by the ASX, with its shares placed in pre-open. The company is very well-funded with $43.7 million at...
View ArticlePharmaxis, Citation Resources among ASX % Gainers intra-day
Wednesday's ASX % Gainers intra-day. CompanyCodeLastChangeVolume Pharmaxis Ltd PXS $0.110 115.69% 7,800,235 Citation Resources CTR $0.002 100% 35,818,366 Boart Longyear BLYR $0.009 80% 734,893 Astro...
View ArticleThese are the biggest ASX% Gainers intra-day
Thursday’s leading ASX % Gainers intra-day. NameCodeLastChangeVolume ORH Limited ASX:ORH $0.002 100% 2,440,680 Pharmaxis Limited ASX:PXS $0.13 58.5% 13,848,020 Fitzroy Resources ASX:FRY $0.009 50%...
View ArticlePharmaxis signs exclusive distribution and supply deal with Chiesi Farmaceutici
Pharmaxis (ASX:PXS) has entered into an exclusive distribution and supply agreement with global pharmaceutical company Chiesi Farmaceutici for commercialisation of its Bronchitol® (mannitol) treatment...
View Article
